Corline Biomedical AB engages in the business of developing a portfolio of drug candidates for use in connection with organ and cell transplantation. The firm is also involved in developing, manufacturing, and marketing heparin-based solutions to improve kidney transplantation, cell therapies, and applications in the evolving field of regenerative medicine. The company was founded in 1991 and is headquartered in Uppsala, Sweden.